Literature DB >> 2572288

Molecular heterogeneity of glucose-6-phosphate dehydrogenase A-.

E Beutler1, W Kuhl, J L Vives-Corrons, J T Prchal.   

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is probably the most common disease-producing genetic polymorphism of humans. Virtually all G6PD-deficient Africans show the G6PD A- phenotype, an electrophoretically rapid, deficient enzyme. The recently acquired ability to identify the point mutations producing the different variants has given us new insights into the population genetics of G6PD variants. Twenty-nine males with the G6PD A- phenotype were studied. They were of African, Mexican, Spanish, and US white ethnic origin. All had the A---G transition at nucleotide 376 characteristic of G6PD A. In each case, one of three additional mutations was present, at nucleotides 202, 680, or 968. That in this population second mutations producing G6PD deficiency occurred only on the genetic background of G6PD A suggests that G6PD A was at one time the most common type of G6PD in Africa. However, the nucleotide sequence of the chimpanzee (Pan troglodytes) G6PD indicates that the primordial human type of G6PD was G6PD B.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572288

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  Genetic predictors for stroke in children with sickle cell anemia.

Authors:  Jonathan M Flanagan; Denise M Frohlich; Thad A Howard; William H Schultz; Catherine Driscoll; Ramamoorthy Nagasubramanian; Nicole A Mortier; Amy C Kimble; Banu Aygun; Robert J Adams; Ronald W Helms; Russell E Ware
Journal:  Blood       Date:  2011-04-22       Impact factor: 22.113

2.  G6PD deficiency and malaria selection.

Authors:  L Luzzatto
Journal:  Heredity (Edinb)       Date:  2011-10-19       Impact factor: 3.821

3.  G6PD A- deficiency and severe malaria in The Gambia: heterozygote advantage and possible homozygote disadvantage.

Authors:  Giorgio Sirugo; Irene M Predazzi; Jacquelaine Bartlett; Alessandra Tacconelli; Michael Walther; Scott M Williams
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

4.  Molecular genetics of the glucose-6-phosphate dehydrogenase (G6PD) Mediterranean variant and description of a new G6PD mutant, G6PD Andalus1361A.

Authors:  J L Vives-Corrons; W Kuhl; M A Pujades; E Beutler
Journal:  Am J Hum Genet       Date:  1990-09       Impact factor: 11.025

5.  Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with asymptomatic malaria in a rural community in Burkina Faso.

Authors:  Abdoul Karim Ouattara; Cyrille Bisseye; Bapio Valery Jean Télesphore Elvira Bazie; Birama Diarra; Tegwindé Rebeca Compaore; Florencia Djigma; Virginio Pietra; Remy Moret; Jacques Simpore
Journal:  Asian Pac J Trop Biomed       Date:  2014-08

6.  A novel G6PD mutation leading to chronic hemolytic anemia.

Authors:  Jenny McDade; Tatiana Abramova; Nicole Mortier; Thad Howard; Russell E Ware
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

7.  Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial.

Authors:  Frank O Odhiambo; Mary J Hamel; John Williamson; Kim Lindblade; Feiko O ter Kuile; Elizabeth Peterson; Peter Otieno; Simon Kariuki; John Vulule; Laurence Slutsker; Robert D Newman
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

8.  Polymorphic sites in the African population detected by sequence analysis of the glucose-6-phosphate dehydrogenase gene outline the evolution of the variants A and A-.

Authors:  T J Vulliamy; A Othman; M Town; A Nathwani; A G Falusi; P J Mason; L Luzzatto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

9.  Impact of the method of G6PD deficiency assessment on genetic association studies of malaria susceptibility.

Authors:  Marla K Johnson; Tamara D Clark; Denise Njama-Meya; Philip J Rosenthal; Sunil Parikh
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

10.  Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria.

Authors:  Zul Premji; Rich E Umeh; Seth Owusu-Agyei; Fabian Esamai; Emmanuel U Ezedinachi; Stephen Oguche; Steffen Borrmann; Akintunde Sowunmi; Stephan Duparc; Paula L Kirby; Allan Pamba; Lynda Kellam; Robert Guiguemdé; Brian Greenwood; Stephen A Ward; Peter A Winstanley
Journal:  PLoS One       Date:  2009-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.